1. Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study. (1st December 2022) Authors: Landis, Megan N.; Arya, Mark; Smith, Stacy; Draelos, Zoe; Usdan, Lisa; Tarabar, Sanela; Pradhan, Vivek; Aggarwal, Sudeepta; Banfield, Christopher; Peeva, Elena; Vincent, Michael S.; Sikirica, Vanja; Xenakis, Jason; Beebe, Jean S. Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 878 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study. (23rd October 2022) Authors: Landis, Megan N.; Arya, Mark; Smith, Stacy; Draelos, Zoe; Usdan, Lisa; Tarabar, Sanela; Pradhan, Vivek; Aggarwal, Sudeepta; Banfield, Christopher; Peeva, Elena; Vincent, Michael S.; Sikirica, Vanja; Xenakis, Jason; Beebe, Jean S. Journal: British journal of dermatology Issue: Volume 187:Number 6(2022) Page Start: 878 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗